Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Peptides designed specifically for fat loss include options beyond the GLP-1 class that may be more accessible from a cost perspective
May administer supportive therapy in toxic liver disease as part of treatment
Companies like Ambience Healthcare ($243M in Series C funding) and Open Evidence (which attracted a reported $100 million-plus round at a $3 billion valuation) are building proprietary clinical tools with deep institutional relationships
Luo QQ, Zhou YF, Chen MY, Liu L, Ma J, Zhang MW, et al
Roivant Sciences Sector: Biopharma and drug development HQ: 151 W 42nd Street, New York, NY Year Founded: 2014 Key Leaders: Matt Gline, CEO Number of Employees: An estimated 501-1000 Stage: Public Financial Snapshot: $12.57 billion market cap Notable Investors: SoftBank Vision Fund, QVT Financial LP, SB Investment Advisers (UK) Limited, FMR LLC (Fidelity), Viking Global Investors LP, BlackRock, Inc., The Vanguard Group, Inc., and Morgan Stanley Key Products: Roivant Sciences manages several subsidiary programs ('Vants') across neurology, immunology, and rare diseases
US$ 22.64
US$ 27.78
US$ 20.18
US$ 26.86
US$ 23.70
US$ 24.29
US$ 27.42
US$ 24.06
US$ 26.04
US$ 25.61
US$ 24.80
US$ 28.33
US$ 20.93
US$ 23.87
US$ 21.29
US$ 24.37
